Pathogen Identification Results in 90 Minutes Direct from Positive Blood Cultures
Faster Results to Help Clinicians Improve Antibiotic Selection and Outcomes for Critical Infections
WOBURN, Mass. and VEDBAEK, Denmark, April 28 /PRNewswire/ -- AdvanDx today announced that it has launched a fast, 90 minutes protocol for all CE-IVD marked PNA FISH(R) tests in Europe. The fast protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization time from 90 minutes to 30 minutes. Clinical validation studies performed at hospitals in the United States and Europe show the two protocols to be 100% equivalent while maintaining the very high (>95%) sensitivity and specificity versus slower, conventional laboratory methods.
Since the first product launch in May 2003, AdvanDx’s PNA FISH tests have provided rapid identification of bloodstream pathogens to help clinicians optimize antibiotic therapy and improve care for patients with critical infections. Clinical studies have shown that implementing PNA FISH tests reduced time to reporting of pathogen identification results by up to 48-72 hours, improved antibiotic selection for patients with bloodstream infections, reduced unnecessary antibiotic use, reduced infection related mortality rates and significantly reduced hospital bed, pharmacy and laboratory costs. (1,2,3,4) With the shortened protocol, labs will be able to provide results even faster to help clinicians further improve antibiotic prescribing and patient care.
“We are very excited to launch the shortened PNA FISH protocol in Europe,” said Thais T. Johansen, President and CEO of AdvanDx. “The faster results will enable laboratories to provide this critical information sooner to clinicians, enabling them to make the most appropriate antibiotic selection and treatment decision as early as possible,” Johansen concluded.
PNA FISH Diagnostic Platform Features:
About PNA FISH(R)
PNA FISH tests enable microbiology labs to provide rapid and accurate identification of bloodstream pathogens directly from positive blood cultures in hours instead of days. Clinical studies show that rapid identification of bloodstream pathogens using PNA FISH tests leads to more appropriate patient therapy that saves lives and reduces unnecessary antibiotic use, patient length of stay and hospital costs.
About AdvanDx
AdvanDx is the world’s leading provider of advanced molecular diagnostic products for the prevention, diagnosis and treatment of life-threatening, bacterial infections. AdvanDx’s easy-to-use products provide fast and accurate results that enable dramatic improvements in patient care and help to save lives and reduce hospital costs.
AdvanDx’s products employ standard laboratory techniques and equipment to reduce startup, implementation, technician and maintenance time, while providing fast results without sacrificing accuracy. Major medical centers, reference labs, government institutions and community hospitals throughout the United States, Europe and Asia rely on AdvanDx products as integral parts of their medical care.
For more information visit www.AdvanDx.com
References
PN1617A
CONTACT: Joen T. Johansen, Director of Marketing for AdvanDx,
+1-339-227-4052, jtj@advandx.com
Web site: http://www.AdvanDx.com/
